Last reviewed · How we verify
simiaowan
simiaowan is a Small molecule drug developed by Guang'anmen Hospital of China Academy of Chinese Medical Sciences. It is currently in Phase 1 development.
Simiaowan is being studied as a potential treatment for preventing acute flares in chronic gout patients who are initiating febuxostat therapy. Clinical trials are comparing the efficacy and safety of simiaowan to a placebo in patients with gout flare.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | simiaowan |
|---|---|
| Sponsor | Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- simiaowan CI brief — competitive landscape report
- simiaowan updates RSS · CI watch RSS
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences portfolio CI
Frequently asked questions about simiaowan
What is simiaowan?
Who makes simiaowan?
What development phase is simiaowan in?
Related
- Manufacturer: Guang'anmen Hospital of China Academy of Chinese Medical Sciences — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing